Pcv112 Cost Utility Analysis of Ticagrelor Removal by Cytosorb® in Patients Requiring Emergent or Urgent Cardiac Surgery in the Uk

Abstract

survival model. The model was based on the survival data from published literature, extrapolated to 10 years (results were based on the restricted mean survival time). In BIA, the number of patients was based on data on MIS-SU-AVR in other countries. The patients using MIS-SU-AVR in the new scenario recruit from cSAVR or TAVI; the proportion was based on current diagnosis-related groups statistics. The cost of the procedure was based on current cSAVR cost, adjusting for the device cost; other costs were based of the National Health Fund data. Results: In the CEA, MIS-SU-AVR offers clinical benefits vs cSAVR and TAVI (0.1 and 1.1 life years gained, respectively) and is cost saving vs TAVI (hence, dominant). The incremental cost effectiveness ratio vs cSAVR amounts to 32,544 EUR (below the official threshold). In the BIA, there would be 102, 182, 429, and 560 MIS-SU-AVR patients in consecutive years. Introducing MIS-SU-AVR would result in net savings ('000s EUR): 73, 131, 305, and 403, respectively. Conclusions: MIS-SU-AVR is cost-effective vs cSAVR and TAVI and its reimbursement would result in net savings in Poland.

Multidisciplinary paper on patient blood management in cardiothoracic surgery in the UK: perspectives on practice during COVID-19

“…Acute coronary syndrome patients receiving dual antiplatelet therapy who need emergent or urgent cardiac surgery are known to be at higher risk of severe bleeding. The use of intraoperative active adsorbers for patients receiving Ticagrelor addresses this issue improving peri- and post-operative outcomes [ 90 ]. The general necessity to reduce ICU stays to a minimum resulted in an even more need for meticulous haemostasis during cardiothoracic surgery.…”